- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01956227
Fall Risk Reduction in Multiple Sclerosis: Exercise Versus Behavior (FARMS-2)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Falls are a serious health concern for persons with multiple sclerosis (MS). Over 50% of persons with MS suffer a fall over a 6-month periodwith the majority of falls resulting in medical attention for injuries (i.e., lacerations, bone fractures, & head injuries). The effects of a fall are often compounded as it can lead to activity curtailment, physiological deconditioning, and institutionalization. Despite the importance of falls in persons with MS, the appropriate prevention strategies (i.e. rehabilitation approaches) are not clear.
It is well known that causes of falls are multifactorial with over 400 risk factors identified. However, it is believed that these factors can be divided into two main classes: intrinsic (e.g. physiological factors) and extrinsic factors. For instance balance dysfunction, spasticity and muscle weakness are physiological risk factors for falls in MS . Behavioral fall risk factors in MS include choosing appropriate footwear, lighting and utilizing appropriate assistive device. There is evidence that both types of risk factors can be minimized with appropriately designed interventions in persons with MS and have been shown to reduce fall risk and incidence in other clinical populations. This has led to calls for the combination of exercise training program that targets specific, modifiable physiological risk factors and educational interventions targeting modifiable behavioral risk factors in persons with MS. However, there is minimal evidence that these interventions in isolation or combination actually reduce fall incidence or risk in persons with MS. This proposal seeks to determine the effectiveness of a combined exercise and educational rehabilitation strategy to prevent falls in persons with MS.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Urbana, Illinois, United States, 61802
- University of Illinois UC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Definite multiple sclerosis diagnosis
- ambulatory
- aged 50-75 years of age
- fallen within 12 months
Exclusion Criteria:
- non-ambulatory
- outside age range
- no fall history
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Home-based Exercise
Participants will be taught a series of exercises targeting balance and lower limb strength in four instructional sessions.
They will be asked to complete exercises 3 times a week for 12 weeks.
Exercise compliance will be recorded with a diary.
|
exercise to look at balance and lower limb strength record in diary
|
Experimental: Education
Participants will attend 4 education sessions focusing on interaction of beliefs, behaviors and symptoms on falls.
They will be taught self-management principles to modify their fall risk.
|
sessions to discuss self-management ideas to modify risk of falling
|
Experimental: Exercise plus education
Participants will attend 2 instructional exercise sessions as well as 2 education sessions.
Participants will be asked to complete exercises at home 3 times per week and engage in behavior to minimize fall risk.
|
combination of exercise sessions with education sessions to modify fall risk
|
No Intervention: Control
Participants will not receive any treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Fall incidence
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physiological Fall Risk
Time Frame: 3 Months
|
Physiological fall risk will be determined by the short form of the Physiological Profile Assessment (PPA)(Lord, 2003).
The PPA is a standardized test battery which assesses vision (edge contrast sensitivity), lower limb proprioception, strength (knee extension), postural sway, and cognitive function (simple hand reaction time).
The outcome of each test will be combined to generate an overall fall risk score
|
3 Months
|
Mobility
Time Frame: 3 months
|
Specific measures of walking speed, endurance, coordination and self-reported walking function scale will be employed to assess overall mobility of each person.
Walking speed was quantified with the Timed 25-Foot Walk (T25W), walking endurance was assessed with the 6-Minute Walk (6MW), and functional mobility was quantified with the Timed Up and Go (TUG) .
The Multiple Sclerosis Walking Scale-12 (MSWS-12) will be used as a self-reported measure of walking impairment.
|
3 months
|
Balance
Time Frame: 3 Months
|
To assess balance (e.g.
postural control), we conducted a clinical assessment To measure balance the Berg Balance Scale (BBS) and self-reports of balance confidence will be used.
The BBS is a clinical assessment of balance.
Scores on the BBS range from 0-56 with higher scores indicating greater balance.
The Activities-Specific Balance Confidence (ABC) scale was used as a measure of balance confidence.
|
3 Months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jacob Sosnoff, University of Illinois at Urbana-Champaign
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NMSS-IL-006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
Clinical Trials on Home-based exercise
-
University of OklahomaNational Institute on Aging (NIA); Milton S. Hershey Medical Center; Case Western...Not yet recruitingPeripheral Artery Disease | ClaudicationUnited States
-
University GhentTerminatedHypermobile Ehlers-Danlos Syndrome | Hypermobility Syndrome | Multidirectional Subluxation of ShoulderBelgium
-
University of WaterlooAlzheimer's AssociationCompletedDementia | Mild Cognitive ImpairmentCanada
-
Uskudar UniversityRecruitingAdolescent Idiopathic ScoliosisTurkey
-
Hacettepe UniversityCompletedKnee OsteoarthritisTurkey
-
University of FlorenceUnknownCardiovascular DiseaseItaly
-
Karolinska InstitutetMayo ClinicNot yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSweden
-
University of Sao PauloCompletedObesity | Bariatric SurgeryBrazil
-
Istanbul UniversityCompleted
-
Cardenal Herrera UniversityConsorci Sanitari de Terrassa. Hospital de TerrassaCompletedChronic Kidney Disease | End-stage Renal DiseaseSpain